Why does the U.S.-only Wegovy pill comparison differ from the global ratio?
In its November 10, 2026 analysis of Q3 2026, Drugnews reports Novo Nordisk’s U.S. Wegovy pill revenue at DKK 4.18 billion, approximately US$630 million. Counting all of Eli Lilly’s US$184 million Foundayo revenue as U.S. sales yields the article’s rounded 3.4x comparison. The U.S. allocation for Foundayo is an explicit analytical assumption.
| Measure | Reported result | Basis |
|---|---|---|
| Wegovy pill / United States | DKK 4.18 billion | Approximately US$630 million |
| Foundayo / assumed United States | US$184 million | All reported revenue allocated to the U.S. for this comparison |
| U.S.-only revenue ratio | 3.4x | Rounded comparison under that assumption |
The comparison is an article calculation, not an independently reported Foundayo U.S. revenue line or a prescription count.
Read the full analysis
Novo Pill Leads Lilly 4x, Lilly Takes 1/3 of Starts — 2026-11-10